HCW Biologics Inc. Cash and Cash Equivalents, Period Increase (Decrease)
HCW Biologics Inc. (HCWB) reported Cash and Cash Equivalents, Period Increase (Decrease) of $6.39 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-05-13
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2022-03-31 was $6.39M.
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was -$3.39M, a 272.04% decline year-over-year.
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was $10.07M, a 203.95% increase year-over-year.
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-06-30 was -$1.81M.
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $3.27M, a 197.71% increase from fiscal 2020.
- HCW Biologics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $1.10M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2022-03-31 | $6.39M 10-Q · filed 2022-05-13 | $2.99M derived: sum of 2 quarters · filed 2022-05-13 | $13.07M derived: sum of 3 quarters · filed 2022-05-13 | $11.26M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $6.68M derived: sum of 2 quarters · filed 2022-03-29 | $4.87M derived: sum of 3 quarters · filed 2022-03-29 | $3.27M 10-K · filed 2022-03-29 |
| 2021-09-30 | $10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $8.27M derived: sum of 2 quarters · filed 2021-11-12 | $6.67M 10-Q · filed 2021-11-12 | $8.64M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-06-30 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$3.40M 10-Q · filed 2021-08-13 | -$1.43M derived: sum of 3 quarters · filed 2022-05-13 | $1.88M derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-03-31 | -$1.60M 10-Q · filed 2022-05-13 | $373.33K derived: sum of 2 quarters · filed 2022-05-13 | $3.69M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.29M derived: sum of 2 quarters · filed 2022-03-29 | $1.10M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$873.02K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$4.19M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |